HC Wainwright Brokers Decrease Earnings Estimates for TCRX

TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) – Research analysts at HC Wainwright cut their FY2026 EPS estimates for shares of TScan Therapeutics in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.84) for the year, down from their prior forecast of ($0.62). HC Wainwright has a “Neutral” rating and a $1.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q4 2026 earnings at ($0.13) EPS, Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.09) EPS, Q4 2027 earnings at ($0.09) EPS, FY2027 earnings at ($0.37) EPS, FY2028 earnings at ($0.28) EPS and FY2029 earnings at ($0.28) EPS.

TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06). TScan Therapeutics had a negative net margin of 2,219.19% and a negative return on equity of 119.44%. The company had revenue of $0.59 million for the quarter, compared to analyst estimates of $0.46 million.

A number of other equities analysts have also issued reports on the company. Benchmark restated a “buy” rating on shares of TScan Therapeutics in a research note on Thursday, August 13th. Wedbush lowered TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price objective on the stock. in a report on Wednesday, September 2nd. Weiss Ratings cut TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Finally, Lifesci Capital downgraded TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $2.67.

View Our Latest Stock Analysis on TScan Therapeutics

TScan Therapeutics Price Performance

Shares of TCRX opened at $0.15 on Tuesday. The firm has a market capitalization of $9.83 million, a PE ratio of -0.16 and a beta of 1.21. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.37 and a quick ratio of 3.37. TScan Therapeutics has a 1-year low of $0.15 and a 1-year high of $1.47. The company’s fifty day moving average price is $0.25 and its 200-day moving average price is $0.80.

Institutional Investors Weigh In On TScan Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TCRX. Public Employees Retirement System of Ohio acquired a new stake in TScan Therapeutics during the second quarter worth about $36,000. Bank of America Corp DE acquired a new position in TScan Therapeutics in the second quarter valued at approximately $48,000. Landscape Capital Management L.L.C. purchased a new stake in TScan Therapeutics in the 2nd quarter worth approximately $25,000. NewEdge Wealth LLC purchased a new stake in TScan Therapeutics in the 2nd quarter worth approximately $90,000. Finally, BlackRock Inc. acquired a new stake in shares of TScan Therapeutics during the 2nd quarter worth approximately $975,000. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

(Get Free Report)

TScan Therapeutics is a clinical-stage biotechnology company developing engineered T cell receptor (TCR) T cell therapies for cancer. Its approach is designed to equip a patient’s T cells to recognize and attack cancer cells bearing specific targets. The company’s research and development programs include therapies for blood cancers and solid tumors. TScan uses its technology platform to identify cancer-associated targets and develop TCRs directed at them, with the goal of creating treatments for patients whose cancers express those targets.

Featured Articles

Earnings History and Estimates for TScan Therapeutics (NASDAQ:TCRX)

Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.